Cannabinoid receptor 1 (CB 1 ) is the principal target of D 9 -tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use. CB 1 is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders. Here, we present the 2.8 Å crystal structure of human CB 1 in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study. The structure of the CB 1 -AM6538 complex reveals key features of the receptor and critical interactions for antagonist binding. In combination with functional studies and molecular modeling, the structure provides insight into the binding mode of naturally occurring CB 1 ligands, such as THC, and synthetic cannabinoids. This enhances our understanding of the molecular basis for the physiological functions of CB 1 and provides new opportunities for the design of next-generation CB 1 -targeting pharmaceuticals.
INTRODUCTION
Marijuana from Cannabis sativa L. has been used for both therapeutic and recreational purposes for many centuries (Lemberger, 1980; Li, 1973) . In the 1940s, chemistry based on compounds isolated from the plant (Wollner et al., 1942) produced novel biologically active molecules (Adams et al., 1948; Ghosh et al., 1940) ; however, it was not until the 1960s that the active constituent of marijuana, D 9 -tetrahydrocannabinol (THC), a terpenoid molecule, was isolated and characterized (Gaoni and Mechoulam, 1964) . This provided an early molecular foundation for medicinal chemists to develop related structural analogs and new synthetic ligands (Makriyannis and Rapaka, 1990; Razdan, 1986) . Initially, due to their lipophilic nature, it was assumed that cannabinoids exerted their effects by perturbing the physical properties of biological membranes (Makriyannis, 2014; Mavromoustakos et al., 1995) . This assumption was challenged with the discovery, cloning, and expression of the first cannabinoid-specific membrane receptor, then designated as the cannabinoid receptor (CB) (Devane et al., 1988; Matsuda et al., 1990) . With the subsequent identification of a second receptor, the designation evolved to CB 1 and CB 2 (Munro et al., 1993) . The discovery of the endogenous agonists to the receptors, the endocannabinoids, anandamide (Devane et al., 1992) , and 2-arachidonoyl glycerol (2-AG) (Mechoulam et al., 1995) soon followed. Cannabinoid receptors belong to the class A G proteincoupled receptor (GPCR) family, signal through inhibitory Ga i/o heterotrimeric G proteins (Howlett, 1985) , and interact with b-arrestins (Jin et al., 1999) . CB 1 is the most highly expressed GPCR in the human brain and is expressed throughout the body, with the highest levels found in the central nervous system (Herkenham et al., 1990) .
Cannabis has been used for centuries in many cultures to treat a wide range of medical conditions. More recently, therapeutic considerations have moved beyond the plant extract to explore and produce more pharmacologically refined compounds. CB 1 -selective small-molecule agonists have shown therapeutic promise in a wide range of disorders, including pain and inflammation (Cravatt and Lichtman, 2004) , multiple sclerosis (Pertwee, 2002; Pryce and Baker, 2015) , and neurodegenerative disorders (Ferná ndez-Ruiz et al., 2015) . The first CB 1 -selective antagonist/inverse agonist, rimonabant (SR141716, Acomplia [Sanofi-Aventis]) (Rinaldi-Carmona et al., 1994) , received approval from the European Medical Agency as an adjunct to diet and exercise for treating obesity (Janero and Makriyannis, 2009 ). Antagonists of CB 1 have been explored as potential therapeutics for obesity-related metabolic disorders (Mazier et al., 2015) , mental illness (Black et al., 2011; Rubino et al., 2015) , liver fibrosis (Mallat et al., 2013) , and nicotine addiction (Schindler et al., 2016) . However, rimonabant and other ligands in its class were not approved in the United States due to concerns about adverse events, such as increased anxiety, depression, and suicidal ideation.
Numerous studies have investigated how ligands binding CB 1 can mediate downstream signaling. While the variety of compounds exhibiting different pharmacological profiles have provided clues regarding CB 1 activation, the molecular details defining the binding modes of both endogenous and exogenous ligands are still largely unknown (Guo et al., 1994; Makriyannis, 2014; Picone et al., 2005) . In order to address this deficit in understanding, we have determined the crystal structure of CB 1 in complex with a tight binding antagonist AM6538. In conjunction with molecular docking, the structure was used to elucidate the binding modes of a diverse set of antagonists/inverse agonists and agonists of CB 1 . The structural details of the cannabinoid receptor reported herein improve our understanding of how ligands engage to modulate the cannabinoid system and provide a useful model to facilitate the design of next-generation pharmaceuticals to avoid unwanted side effects. The findings provide insight into mechanisms of slow dissociation of antagonists, which may potentially translate into long acting pharmacological effects.
RESULTS

Synthesis of CB 1 Stabilizing Antagonist AM6538 for Structural Studies
One of the key factors facilitating the structure determination of CB 1 (Figure 1 ) is utilization of the antagonist AM6538, the synthesis of which resulted from the strategic modification of rimonabant to enhance its ability to stabilize the ligand-receptor complex and promote CB 1 crystal formation. In contrast with rimonabant, the 5-phenyl ring substituent was modified so as to introduce motifs (ex. alkyne unit) that could favor increased affinity for the CB 1 receptor (Tam et al., 2010) . The rimonabant analog, AM251, (1, Figure 2A ) (Lan et al., 1999) , a compound that has been used extensively as a pharmacological standard CB 1 -selective antagonist, was used as the precursor in the AM6538 synthetic process. Synthesis of AM6538 involves the functionalization of the iodo substituent at the para position of the 5-phenyl ring in AM251 with an acetylenic chain system consisting of four carbons and substituted at the omega carbon. To this end, we initially focused on targeting cysteine residues within CB 1 by introducing suitable electrophilic groups Li et al., 2005; Mercier et al., 2010; Picone et al., 2005; Szymanski et al., 2011) at the fourth carbon of the alkyne unit, capable of forming a covalent bond with the cysteine thiol group. For AM6538, we introduced at this position a nitrate group (ONO 2 ) whose role was to serve as a polar group, which may be displaced by a suitable nucleophile (e.g., thiol) (Pattison and Brown, 1956; Yeates et al., 1985) at or near the binding domain or alternatively bind as an intact group so as to obtain a non-covalent, near-irreversible attachment by interacting with hydrogen bonding amino acid residues, as well as residues capable of p-p interactions. In the present study, affinity mass spectrometry analysis suggests that AM6538 reacts with CB 1 as an intact molecule with no evidence of covalent modification of relevant cysteine residues.
AM6538 was a strong candidate for crystallographic studies of the receptor based on its high affinity and wash-resistant binding to CB 1 as determined by radioligand competition assays against the tritiated agonist, [
3 H]-CP55,940 (K i = 3.4 ± 1.0 nM) ( Figures 2B-2D ). This is in contrast to rimonabant, which can be readily washed out of membranes, permitting subsequent radioligand binding ( Figures 2B-2D) . Importantly, the crystallized CB 1 construct (described below) has comparable affinity for AM6538 as the wild-type receptor (K i = 5.1 ± 0.9 nM). In functional assays, AM6538 is a competitive antagonist of the effects of CP55,940 and THC on CB 1 -mediated inhibition of adenylyl cyclase activity and b-arrestin2 recruitment in overexpression systems (Figures S1A and S1B and Table S1 ). Competitive antagonism was confirmed by the [ 35 S]-GTPgS binding assays performed in mouse cerebellum ( Figure S1C ). For comparison purposes, competitive antagonism was demonstrated for rimonabant in the same systems ( Figure S1 and Table S1 ).
Structure Determination of CB 1 -AM6538 Complex
To facilitate crystallization, it was necessary to modify the wild-type (WT) CB 1 sequence. Construct optimization proced- Figure S1 and Table S1 .
ures (Lv et al., 2016) [1995] ). The modified CB 1 construct was inserted into a pTT5 vector for expression in HEK293F cells to generate protein ( Figure S2D ) that formed crystals in lipidic cubic phase supplemented with cholesterol ( Figure S3E ); the crystals diffracted to 2.8 Å (Table 1) . Based on affinity mass spectrometry analysis, intact AM6538 is associated with the CB 1 protein ( Figure S3F ). Electron density with three branches was observed near the orthosteric binding site and modeled as core AM6538 atoms with the terminal nitrate group omitted ( Figures 3D and S3) . A molecular dynamics (MD) simulation was performed on the CB 1 -AM6538 complex with the nitrate group intact and modeled through docking analysis, and the results revealed that the root mean square fluctuation (RMSF) values for the nitrate group and the hinge carbon atom are higher, suggesting that the nitrate group is more mobile than other atoms in AM6538 (Figure S4B) . As a modeled ligand with other possibilities to fit the electron density, further studies on ligand binding are under investigation.
Structural Features of CB 1 in Complex with AM6538
The overall CB 1 structural fold shares a similar architecture with previously solved class A GPCR structures, containing seven transmembrane (7TM) a-helices (I to VII) connected by three extracellular loops (ECL1-3), three intracellular loops (ICL1-3), and an amphipathic helix VIII ( Figures 1A and S3A) . The non-truncated part of the N terminus of CB 1 , residues 99-112, forms a V-shaped loop, which inserts into the ligand-binding pocket and functions as a plug, restricting access to the pocket from the extracellular side ( Figures 1A and 1B) . While the influence of crystal packing interactions on the conformation of the N terminus ( Figure S3B ) cannot be ruled out, it is interesting to note that the N terminus has been consistently observed in an ordered form in the structures of the related lipid receptors LPA 1 (lysophosphatidic acid receptor 1) (Chrencik et al., 2015) and S1P 1 (sphingosine 1-phosphate receptor 1) and that the function of CB 1 is very sensitive to the presence of the ordered portion of the N terminus (Andersson et al., 2003; Fay and Farrens, 2013) . ECL2 in CB 1 consists of 21 residues folding into an intricate structure that projects four residues (268-271) into the binding pocket. Previous work has shown that the four residues are important for mediating interactions with certain classes of ligands (Ahn et al., 2009; Bertalovitz et al., 2010) and that the two cysteines (Cys257 and Cys264) in ECL2 are critical to the function of CB 1 (Fay et al., 2005) . In the structure, the conformation of ECL2 is constrained by the presence of an intraloop disulfide bond (Cys257-Cys264) ( Figure 1B ) previously found in the structures of the closely related LPA 1 and S1P 1 receptors. The highly conserved disulfide bond between ECL2 and helix III (Cys 3.25 ) in most class A GPCRs is lacking in all three lipid receptor structures.
AM6538 Interactions in CB 1 Ligand-Binding Pocket
The position of the ligand-binding pocket of CB 1 is different from the previously described orthosteric binding sites of other class A GPCRs. AM6538 lies quite low in the binding pocket of CB 1 , immediately above the conserved Trp356 6.48 ( Figures 3A and   3B ). The ligand adopts an extended conformation with the ligand strain close to its local minimum as determined by quantum mechanical calculations ( Figure S3D ). AM6538 forms mainly hydrophobic interactions with ECL2 and the N terminus, as well as with all CB 1 helices except helix IV (Figures 3A and 3B). As described above, the ligand has a pyrazole ring core with three functional groups. For clarity, we have termed the 2,4-dichlorophenyl ring ''arm 1,'' the 4-aliphatic chain substituted phenyl ring ''arm 2,'' and the piperidin-1-ylcarbamoyl ''arm 3'' ( Figure 3C ). The pyrazole ring core (including the 4-methyl group) is situated between helices II and VII, forming hydrophobic interactions with the side chains of Phe170 2.57 , Phe379 7.35 , and Ser383 7.39 ( Figure 3C ) and is capped by the N-terminal loop interactions (Met103 N-term ). Arm 1 is located in a narrow side pocket ( Figure 3B) Figure 3C ). The 2,4-dichlorophenyl ring in arm 1 fits well into the shape of the narrow side pocket ( Figure S3C ), which explains why 2,4-dichloro or 2-chloro substitutions result in optimal binding (Lange and Kruse, 2005) .
Arm 2 of the ligand extends toward a long, narrow channel ( Figure 3B ) formed by helices III, V, VI, and ECL2. The phenyl group in arm 2 establishes p-p interactions with Phe102
ECL2 , and Trp356 6.48 ; hydrophobic interactions with Figure 3C ).
Interestingly, the binding mode of the long hydrophobic chain is similar to that of ML056 with the S1P 1 receptor ( Figure 3B ), implying that this could be a conserved binding pocket for long aliphatic chains in lipid-binding receptors. In regards to the nitrate group that has not been observed in the crystallographic structure, our docking experiments define a domain in which the nitrate group is interacting with residues Thr197 3.33 , Tyr275 5.39 , and Trp279 5.43 through hydrogen bonding and p-p interactions ( Figure S4A ).
Finally, arm 3 extends toward a gap constituted by helices I, II, VII capped by the N-terminal loop ( Figure 3B ). It forms interactions with hydrophobic residues, Met103 N-term Figure 3C ). Unlike the p-p interactions formed by the other two arms, the interactions between arm 3 and the receptor are non-specific. Among the interactions between AM6538 and CB 1 , Phe170 2.57 plays an important role by interacting with the pyrazole ring core, as well as rings in arm 1 and arm 3. Moreover, Phe170 2.57 is pushed by the ligand to move toward helix I, resulting in a tilt of the last two turns (residues 170-177) of helix II toward helix I, compared to S1P 1 and LPA 1 , the two closest homologs ( Figures 4A and 4B ). This tilted helix II, in turn, pushes (C) Schematic representation of interactions between CB 1 and AM6538. The 2,4-dichlorophenyl ring in the red circle is termed as arm 1; the 4-aliphatic chain substituted phenyl ring in the blue circle is termed as arm 2; the piperidin-1-ylcarbamoyl in the green circle is termed as arm 3. The nitrate group, which was not observed in the electron density, is shown in gray.
(D) Electron density maps calculated from the refined structure of the CB 1 -AM6538 complex. jFoj-jFcj omit map (blue mesh) of the ligand AM6538 is shown (contoured at 3 s).
See also Figure S3 .
helix I by about 7 Å , mainly due to interactions with the two bulky residues Phe170 2.57 and Phe174 2.61 . The role of Lys192 3.28 in CB 1 has been intensively researched. It was reported that Lys192Ala/Lys192Gln/Lys192Glu mutants decreased the affinities of several agonists such as CP55,940, HU-210, and anandamide (Chin et al., 1998; Hurst et al., 2002; Pan et al., 1998; Song and Bonner, 1996) . Previously, it was suggested that Lys192 3.28 has direct interactions with CB 1 ligands. However, in our CB 1 structure, Lys192 3.28 does not interact directly with AM6538. Instead, it forms a salt bridge/hydrogen bond network that stabilizes the conformation of ECL1, the N terminus, and the extracellular parts of helices II and III. The side chain of Lys192 3.28 points away from the binding pocket and forms salt bridges with Asp176 2.63 and Asp184 ECL1 , while Asp184 ECL1 further stabilizes the N terminus by forming a hydrogen bond with the backbone of Phe102 N-term ( Figure 4C ).
Structural Comparison of the CB 1 , LPA 1 , and S1P 1 Receptors CB 1 , LPA 1 , and S1P 1 receptors all bind lipid-derived endogenous ligands (anandamide/sn-2-arachidonoylglycerol, sphingosine-1-phosphate, lysophosphatidic acid) (Shimizu, 2009) . Early sequence analysis revealed that CB 1 has a moderate sequence identity with LPA 1 (13% overall, 28% in TM regions) and S1P 1 (14% overall, 27% in TM regions) (Bramblett et al., 1995; Isberg et al., 2016 ) ( Figure S5 ). Crystal structures of LPA 1 (Chrencik et al., 2015) and S1P 1 have been recently determined. The main structural difference between the three lipid receptors occurs in the extracellular portion, with the most striking being the unique conformation of the N-terminal loop of CB 1 (Figures 4A and 4B) . For all three receptors, the N terminus has a role in ligand recognition. Comparing the ligand binding positions of the three receptors, AM6538 lies more horizontally than the ligands in LPA 1 and S1P 1 , with arm 1 inserted deeper into the side pocket ( Figure 4A ). Consistently, the N-terminal loop in CB 1 is positioned deeper into the binding pocket compared to the N-terminal helices of LPA 1 and S1P 1 , which are both positioned as a cap on their respective ligand binding pockets. As a consequence, helix I of CB 1 is pushed outward $7 Å relative to LPA 1 and S1P 1 by arm 2, opening a wider gap between helices I and VII than what was observed in LPA 1 and S1P 1 ( Figure 4A ). Moreover, helix II and ECL1 change their conformation in CB 1 , with helix II shifting 2 Å further from the binding pocket compared with LPA 1 and S1P 1 , and ECL1 changing from a short helical region in LPA 1 and S1P 1 to a loop in CB 1 ( Figure 4B ). These conformational changes effectively enlarge the binding pocket of CB 1 , allowing access to the re-entrant N-terminal loop, and contribute to the extensive surface area and multiple subpockets associated with CB 1 . Finally, the ECL3 region of CB 1 differs from that of its related receptors by a three helical turn extension of helix VII, which increases the rigidity and presumably decreases the flexibility of this loop region in CB 1 ( Figure 4A ). The arrangement of Lys192 3.28 in CB 1 is unique when compared with its equivalent residue Arg 3.28 in LPA 1 and S1P 1 .
In LPA 1 and S1P 1 , Arg 3.28 points into the binding pocket forming a strong interaction with the phosphate head group of the ligands ( Figures 4D and 4E) ; it is stabilized by the negatively charged or polar residue 3.29 (Gln125 in LPA 1 and Glu121 in S1P 1 ). However, in CB 1 the environment near Leu193 3.29 and the ligand is hydrophobic, thus, it is energetically favorable for the positively (B) 90 rotation of (A) for a top view of CB 1 with structurally divergent regions of LPA 1 (4Z34) and S1P 1 (3V2Y) overlaid. CB 1 shows a conserved conformation of ECL2 (blue) with the other two receptors, helix II is shifted out 2 Å (purple helix). (C-E) The interaction network of position 3.28 of CB 1 (K192), LPA 1 (R124), and S1P 1 (R120). Polar interactions are represented by black dashed lines. (C) CB 1 is shown in gray cartoon, AM6538 is shown in green sticks and the key residues are shown in blue sticks; (D) LPA 1 is shown in gray cartoon, ONO-9780307 is shown in purple-blue sticks and the key residues are shown in cyan sticks; (E) S1P 1 is shown in gray cartoon, ML056 is shown in orange sticks and the key residues are shown in pink sticks. See also Figure S5 .
charged Lys192 3.28 to point away from the binding pocket (Figure 4C) . In fact, Lys192 3.28 functions as a stabilization anchor by forming a salt bridge/hydrogen bond network instead of directly interacting with the ligand as Arg 3.28 in LPA 1 and S1P 1 . Another major difference of the endogenous ligands of CB 1 (anandamide, 2-AG), LPA 1 (LPA) and S1P 1 (S1P) is the head group. The heads of LPA 1 and S1P 1 ligands are negatively charged phosphate groups, while the heads of CB 1 ligands are neutral. In fact, phosphorylation of the head group of CB 1 ligands anandamide and 2-AG would transform them into ligands of LPA 1 (Chrencik et al., 2015) .
Binding Modes of Representative Antagonists to CB 1
We performed docking of AM6538 and three CB 1 antagonists: rimonabant, otenabant, and taranabant ( Figure 5 , Table S2 ), which represent diverse scaffolds of CB 1 antagonists used in clinical trials. For each compound, the top one ranked pose was used for analysis. The docking pose of AM6538 reproduces the crystallographic pose ( Figure S4A) , with a root mean square deviation (RMSD) of 0.55 Å . For the three antagonists, their first-ranked docking poses resemble that of AM6538 in the crystal structure, with three arms that fit into the three branches of the binding pocket, as described in the AM6538 binding mode ( Figure 5A ). As denoted for AM6538, the arms in the side pocket, long channel, and gap are termed arm 1, arm 2, and arm 3 ( Figure 5B ). The scaffolds of arm 1 and arm 2 of the three antagonists are very similar to each other, and so are the docking poses. The biggest difference is from arm 3, yet they are all quite bulky, which we speculate is the signature for CB 1 antagonists. Taranabant has the highest affinity with CB 1 among the three ligands (Table S2) . It does not have a rigid aromatic ring at the core, allowing its arm 2 and arm 3 to have more freedom to form stronger interactions with surrounding residues ( Figure 5C (B) Chemical structures of rimonabant, otenabant, and taranabant. The red/blue/green rectangles highlight previously described ''arms'' of the molecule termed arm 1/arm 2/arm 3 (see Figure 3C ). (C) Predicted binding modes of rimonabant (blue sticks), otenabant (raspberry sticks), and taranabant (brown sticks) with CB 1 . The interacting residues are shown in yellow sticks, and H178 is shown in green sticks. See also Figure S4 and Table S2. appreciable effect on antagonist binding, further supporting the importance of the hydrophobic interactions at this site ( Figures  S4G and S4H ). In addition, we performed 50 ns MD simulations to visually assess the predicted ligand-receptor interactions, starting from the docking poses. The RMSD values of AM6538, rimonabant, and otenabant are about 1.4 Å . For taranabant, the value is larger (about 3 Å ), in accordance with its lack of the core aromatic ring (Figures S4C-S4F ). The predicted interactions of the ligands are conserved during the short MD simulations. The central structure of AM6538 in MD simulation is closest to the docking pose. Figure S4G ). Anandamide and 2-AG were predicted to adopt a C-shaped conformation and occupy a similar space as THC ( Figures 6C and 6D ). Their hydrophilic heads are sandwiched between the N-terminal loop and ECL2, and their long aliphatic tails extend deeper into the long channel. JWH-018 and WIN 55,212-2, however, are predicted to bind deeper in the pocket than THC ( Figures 6E and 6F ). Both the indole rings and naphthalene rings form p-p interactions with Phe268 ECL2 . The N-substituents reach the end of the long channel and interact with helix V. The binding mode of JWH-018 and WIN 55,212-2 is supported by mutations on helix V (McAllister et al., 2003; Song et al., 1999) and SAR study of N-alkyl chain length (Aung et al., 2000 Figure S4I ). While these mutations dramatically affected CP55,940 agonism, they had no impact on antagonist/inverse agonist (AM6538 or rimonabant) displacement of agonist (Figure S4J) , further supporting the predicted binding pose of CP55,940 ( Figure 6G ).
DISCUSSION
The ligand used in this study, AM6538, was designed with the aim of stabilizing the ligand-CB 1 receptor complex and promoting CB 1 crystal formation. For this purpose, our approach focused on the use of the substituted biarylpyrazole chemotype based on the structure of rimonabant for obtaining highly utilized proprietary probes. Within this class of compounds, a slight modification of the chemotype led to AM251, a commonly used CB 1 inverse agonist/antagonist (Lan et al., 1999) , and AM281, a CB 1 antagonist whose radiolabeling produced the first in vivo imaging agent for labeling CB 1 in nonhuman primates and humans (Berding et al., 2004; Gatley et al., 1998) . AM6538 acts as a CB 1 stabilizing antagonist, and the ligand was effective in allowing structural determination of CB 1 . AM6538 reacts as an intact molecule with no crystallographic evidence of covalent binding while at the same time not revealing the location of the terminal nitrate group in the X-ray structure. While radioligand binding studies demonstrate that AM6538 binds tightly to the receptor, the precise mode of action for stabilizing the receptor remains to be determined.
To date, there remains considerable controversy with regards to CB 1 ligands and their diverse medical applications. This is likely due in part to the wide availability and illicit nature of the most famous CB 1 pharmaceutical, marijuana. Marijuana has been widely used across many cultures to treat multiple conditions, with most of the results relayed via oral tradition, anecdote, political position, or with economic interest preventing an objective interpretation of therapeutic efficacy in any particular disease state (Whiting et al., 2015) . The medicinal marijuana movement continues to gain support, and clinical trials with well-defined endpoints will continue to educate the medical and pharmaceutical communities regarding the relative benefits and drawbacks of targeting this physiological system. The crystal structure of CB 1 in complex with AM6538 reveals an expansive and complicated binding pocket network consisting of multiple sub-pockets and channels to various regions of the receptor. The three-arm ligand structure is common to CB 1 antagonists and inverse agonists and may be critical for stabilizing the inherent flexibility of the native receptor in a non-signaling conformation. Combining the 3D structure of CB 1 and molecular docking of the three representative antagonists, which act as inverse agonists, rimonabant, otenabant, and taranabant, the role of each arm is clearly illustrated. Arm 1 is crucial for high affinity binding, while arm 2 extends into the long channel. An aliphatic or aromatic ring on arm 3 pushes on helices I and II, causing them to bend outward, and potentially modulating the pharmacological signaling state of the receptor. Together with structure and modeling data, we speculate that a bulky ring on arm 3 is essential for CB 1 antagonism. This observation provides direction for designing more diverse compounds as we have learned that variable chemical groups are tolerated at the core of arm 3, a long carbon chain can be added at the para-position of the phenyl ring in arm 2. For example, introduction of a 4-cyanobut-1-ynyl at arm 2 Figure S4 and Table S2. produces AM6545 (Table S2) , a high-affinity CB 1 neutral antagonist (Tam et al., 2010) .
Understanding the nuances of CB 1 binding and activation is important, as human use has noted differences between the phytocannabinoid agonist THC and the synthetic cannabinoid constituents of ''Spice'' or ''K-2'' such as JWH-018. In general, cannabinoid agonists are routinely abused substances; yet, while overdose of THC/marijuana has not been documented, there have been cases of severe and even deadly responses to the ingestion of such synthetic mixtures resulting in federal restrictions by many countries, including the US. It remains unclear as to why THC can have such a high safety margin, while the synthetic cannabinoid constituents can prove toxic with varying severities of serious side effects (Hermanns-Clausen et al., 2013) . Going forward, the study of cannabinoids present in Cannabis sativa will provide clues to its high efficacy and safety margins and may continue to inspire a rich source of pharmacologically refined compounds and novel therapeutics; the utility of the crystal structure may provide inspiration for drug design toward refining efficacy and avoiding adverse events.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Experimentally naive mice (C57BL/6J) were purchased from Jackson Labs at 9 weeks of age and were housed in groups of five per cage in a specific-pathogen free facility, under a 12-h light-dark cycle with food and water ad libitum. At $16 weeks of age, mice were euthanized by cervical dislocation prior to cerebellum dissection. A total of four mice were used to generate 4 independent experiments for assessing Flash column chromatography was performed on a Biotage Isolera Spektra system with UV collections at 254 and 280 nm using Luknova flash columns preloaded with normal phase silica gel (50 mm). All moisture sensitive reactions were performed under an atmosphere of high-purity argon while using oven-dried glassware. The intermediates and final compounds were characterized using a combination of 1 H NMR, 13 C NMR and LC/MS techniques. The LC/MS analysis was performed using a Waters MicroMass ZQ system (electrospray ionization mode) equipped with a Waters 2525 binary gradient module, a Waters 2996 photodiode array detector, a Waters 2424 ELS detector, two Waters 515 HPLC pump, a fluidics organizer and a pump control module II. Compounds were analyzed with gradient elution using acetonitrile/water as the mobile phase and an XTerra MS C18 or an XTerra MS C8, 4.6 mm 3 50 mm column (5 mm). Melting-points were recorded on a Fisher Scientific apparatus. IR spectra were obtained on a PerkinElmer Spectrum One FT-IR spectrometer. Elemental analyses were performed using a PerkinElmer Series II 2400 CHNS analyzer. 4-(4-(1-(2,4-dichlorophenyl)-4-methyl-3-(piperidin-1-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)but-3-yn-1-yl methanesulfonate (2) To a stirred solution of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (Lan et al., 1999) (1, 1.1 g, 2 mmol) in DMF (30 ml), under argon was added but-3-yn-1-yl methanesulfonate (Tang and Prusov, 2012) (888 mg, 6 mmol), and Hü nig's base (1.9 mL 20 mmol). The reaction mixture was degassed by introducing a steady stream of argon into the solution for 5 min and to this was added tetrakis(triphenylphosphine)palladium (0) (231 mg, 10 mol%) and CuI (76 mg, 20 mol%). The resulting mixture was stirred for 3 hr at room temperature. The solvent from the reaction mixture was removed in vacuo at 70 C and the residue was dissolved in dichloromethane (100 ml) and washed with deionized water (2 3 $50 mL). The organic layer was separated, dried over anhydrous MgSO 4 , filtered and the filtrate was removed in vacuo. The residue obtained was purified by flash column chromatography on silica gel (n-hexane/AcOEt = 1/1) to provide 2 as a white solid (511 mg, 45%); m.p 176- 144.7, 143.6, 136.2, 136.1, 133.2, 132.0, 130.8, 130.5, 129.7, 128.8, 128.1, 123.5, 118.5, 85.8, 82.5, 67.4, 57.3, 38.0, 25.7, 23.6, 21.0, 9.6 ; ES m/z 575.1710 (M + +H). 1-(2,4-dichlorophenyl)-5-(4-(4-iodobut-1-ynyl)phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (3). To a stirred solution of 2 (500 mg, 0.86 mmol) in anhydrous acetone (50 ml), under argon was added sodium iodide (1.3 g, 8.6 mmol) and tetrabutylammonium iodide (64 mg, 0.17 mmol). The resulting reaction mixture was refluxed overnight. The solvent from the reaction mixture was removed in vacuo and the residue was dissolved in dichloromethane (75 ml) and washed with deionized water (2 3 $50 mL). The organic layer was separated, dried over anhydrous MgSO 4 , filtered and the filtrate was removed in vacuo. The residue obtained was purified by flash column chromatography on silica gel (n-hexane/AcOEt = 7/3) to provide 3 as a white solid (326 mg, 62%); m.p 171- 2, 144.7, 143.7, 136.3, 136.1, 133.2, 132.0, 130.8, 130.6, 129.6, 128.6, 128.1, 123.9, 118.5, 90.3, 81.9, 57.3, 25.7, 24.8, 23.6, 9.6, 1.6; IR (neat) 3308, 2929 IR (neat) 3308, , 2851 IR (neat) 3308, , 2787 IR (neat) 3308, , 2509 IR (neat) 3308, , 2160 IR (neat) 3308, , 2031 IR (neat) 3308, , 1689 IR (neat) 3308, , 1524 IR (neat) 3308, , 1486 IR (neat) 3308, , 1245 ; ES m/z 607.1102 (M + +H).
4-(4-(1-(2,4-dichlorophenyl)-4-methyl-3-(piperidin-1-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)but-3-yn-1-yl nitrate (4, AM6538).
To a stirred solution of 3 (300 mg, 0.5 mmol) taken in anhydrous acetonitrile (30 ml), under argon was added silver nitrate (100 mg, 0.6 mmol). The resulting reaction mixture was heated to 70 C for 1 hr. The contents were cooled to room temperature and the solids were filtered over a celite pad. The filtrate was removed in vacuo and the residue was dissolved in dichloromethane (75 ml) and washed with deionized water (2 3 $50 mL). The organic layer was separated, dried over anhydrous MgSO 4 , filtered and the filtrate was removed in vacuo. The residue obtained was purified by flash column chromatography on silica gel (n-hexane/AcOEt = 6/4) to provide 4 (AM6538) 2, 144.7, 143.6, 136.2, 136.1, 133.2, 132.0, 130.8, 130.5, 129.7, 128.8, 128.1, 123.5, 118.5, 85.3, 82.4, 70.4, 57.3, 25.7, 23.6, 18.9, 9.6; IR (neat) 3319, 2935 IR (neat) 3319, , 2857 IR (neat) 3319, , 2811 IR (neat) 3319, , 2502 IR (neat) 3319, , 2160 IR (neat) 3319, , 2031 IR (neat) 3319, , 1976 IR (neat) 3319, , 1682 IR (neat) 3319, , 1616 IR (neat) 3319, , 1528 IR (neat) 3319, , 1488 IR (neat) 3319, , 1277 
Rational Design of Thermostabilizing Mutations of CB 1
To improve general stability and homogeneity of the detergent-stabilized CB 1 , mutations were rationally designed. A 3D homology model of human CB 1 was constructed and refined with ICM (Abagyan and Totrov, 1994) using the X-ray structure of sphingosine 1-phosphate receptor 1 (S1P 1 receptor, PDB: 3V2W) as a template. Best scoring substitutions were visually inspected and evaluated from the evolutionary conservation perspective resulting in a list of proposed substitutions. The predicted substitutions were analyzed for improvement of the receptor monodispersity (as evidenced by SEC traces) and thermal stability (as evidenced by increase in Tm in the CPM assay (Alexandrov et al., 2008) .
Protein Engineering for Structure Determination
The sequence of the human CB 1 gene was synthesized by GenScript. The Flavodoxin (PDB: 1I1O, MW 14.9kDa, with Y98W mutation) fusion protein was fused to the third intracellular loop of the human CB 1 gene, using overlapping PCR. The construct has truncations of the CB 1 residues 1-98, 307-331 and 415-472. The resulting CB 1 -Flavodoxin chimera sequence was subcloned into a modified mammalian expression pTT5 vector, which contains a haemagglutinin (HA) signal sequence, a FLAG tag and 10 3 His tag, followed by a tobacco etch virus (TEV) protease cleavage site, before the N terminus of the chimera sequence. The CB 1 gene was further modified by introducing four rationally designed mutations, Thr210 Protein Expression in Mammalian Expression System HEK293F cells (Invitrogen) were grown in suspension starting from the densities at 0.2-0.3 3 10 6 in a humidified incubator with 5% CO 2 at 37 C with a shake speed of 130rpm. Passage cells when the cell density reaches to 1.6-1.8 3 10 6 cells/ml, about every 2-3 days. CB 1 -Flavodoxin construct was transfected and expressed in HEK293F cells (Invitrogen) (Passage number is 12-20) using the FreeStyle TM 293
Expression system (Invitrogen). Briefly, HEK293F cells were seeded on day 0 at 6 3 10 5 cells/ml in freeStyle 293 expression medium (Invitrogen). On day 2 the transduction was performed at a cell density of 1.0 to 1.2 3 10 6 cells/ml and the cell viability over 95% using PEI-DNA complexes. Approximately 48 hr post-transfection, cells were harvested by centrifugation at 400 g for 20 min at 4 C.
Protein Purification
Frozen cell pellets were thawed and lysed by repeated washing and centrifugation in the hypotonic buffer of 10 mM HEPES (pH 7.5), 10 mM MgCl 2 , 20 mM KCl, and the high osmotic buffer of 10 mM HEPES (pH 7.5), 1.0 M NaCl, 10 mM MgCl 2 , 20 mM KCl, with EDTAfree complete protease inhibitor cocktail tablets (Roche). The washed membranes were suspended in hypotonic buffer with 30% glycerol and flash-frozen with liquid nitrogen and stored at À80 C until further use. Purified membranes were thawed at room temperature and incubated with 20 mM AM6538 and inhibitor cocktail at 4 C for 3 hr. The membranes were further incubated with 1.0 mg/ml iodoacetamide (Sigma) for 1 hr. The membranes were solubilized in the buffer containing 50 mM HEPES (pH 7.5), 500 mM NaCl, 1% (w/v) n-dodecyl-beta-D-maltopyranoside (DDM, Anatrace) and 0.2% (w/v) cholesterol hemisucinate (CHS, Sigma-Aldrich) at 4 C for 2.5-3 hr. The supernatants containing the solubilized CB 1 proteins were isolated by high-speed centrifugation, and then incubated with TALON IMAC resin (Clontech) and 20 mM imidazole, at 4 C overnight. The resin was washed with 15 column volumes of washing buffer I containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 30 mM imidazole and 20 mM AM6538, and 5 column volumes of washing buffer II containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 50 mM imidazole and 20 mM AM6538. The protein was eluted using 2.5 column volumes of elution buffer containing 25 mM HEPES (pH 7.5), 500 mM NaCl, 10% (v/v) glycerol, 0.02% (w/v) DDM, 0.004% (w/v) CHS, 250 mM imidazole and 10 mM AM6538. A PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein was treated overnight with TEV protease to cleave the N-terminal FLAG/His tags from the proteins.
Affinity Mass Spectrometry Analysis of AM6538
The CB 1 protein co-purified with AM6538 was first desalted using PD MiniTrap G-25 column cartridge to deplete free ligands. Then the protein complex sample ($1 mg) was filtered through 30 kDa MW cutoff ultrafiltration membrane (Sartorius, Germany) by centrifugation at 13,000 g for 10 min at 4 C in the buffer containing 150 mM ammonium acetate, 0.02% (w/v) DDM and 0.004% (w/v) CHS. The protein complexes retained on the ultrafiltration membrane was transferred to a new centrifugal tube. The ligands were dissociated from the complexes with 90% methanol and separated from the denatured protein by centrifugation at 13,000 g for 20 min at 25 C. The supernatant was dried out in speed vacuum, reconstituted in 50% methanol, diluted by 50-fold prior to LC-MS analysis using Agilent 6230 TOF equipped with an Agilent 1260 HPLC system. The compound was eluted with 95% methanol/0.1% formic acid from a Hypersil GOLD C18 column (2.1 mm 3 100 mm, 3 mm, Thermo Fisher Scientific, USA) at a flow rate of 0.4 mL/min. Full-scan mass spectra were acquired in the range of 100-1000 m/z on Agilent 6230 TOF with major ESI source settings: voltage 3000 V, gas temperature 350 C, fragmentor 100 V.
QUANTIFICATION AND STATISTICAL ANALYSIS
Concentration-response curves for cAMP and b-arrestin2 are presented as % of CP55,940 or THC at 1 mM, as indicated. Concentration-response curves were fit to a non-linear regression (three parameter) model to determine EC 50 and E max , or a Gaddum/Schild EC 50 shift global non-linear regression model in Prism (v. 6.0, GraphPad Software Inc., San Diego, CA), as indicated. In order to best fit data to the Gaddum/Schild EC 50 shift global non-linear regression, pEC 50 , pA 2 , Hill slope, E max , and E min were shared for all datasets. Schild slope was constrained to unity after determining a competitive antagonism model (i.e. Schild slope = 1) was the preferred model for these data.
DATA AND SOFTWARE AVAILABILITY Data Resources
The accession number for the coordinates and structures factors of CB1_AM6538 reported in this paper is PDB: 5TGZ.
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